JP2022523712A5 - - Google Patents

Info

Publication number
JP2022523712A5
JP2022523712A5 JP2021544181A JP2021544181A JP2022523712A5 JP 2022523712 A5 JP2022523712 A5 JP 2022523712A5 JP 2021544181 A JP2021544181 A JP 2021544181A JP 2021544181 A JP2021544181 A JP 2021544181A JP 2022523712 A5 JP2022523712 A5 JP 2022523712A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
weight
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021544181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523712A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015002 external-priority patent/WO2020159824A1/en
Publication of JP2022523712A publication Critical patent/JP2022523712A/ja
Publication of JP2022523712A5 publication Critical patent/JP2022523712A5/ja
Pending legal-status Critical Current

Links

JP2021544181A 2019-01-29 2020-01-24 治療用化合物および組成物 Pending JP2022523712A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962798012P 2019-01-29 2019-01-29
US62/798,012 2019-01-29
PCT/US2020/015002 WO2020159824A1 (en) 2019-01-29 2020-01-24 Therapeutic compounds and compositions

Publications (2)

Publication Number Publication Date
JP2022523712A JP2022523712A (ja) 2022-04-26
JP2022523712A5 true JP2022523712A5 (enExample) 2023-01-20

Family

ID=71841895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544181A Pending JP2022523712A (ja) 2019-01-29 2020-01-24 治療用化合物および組成物

Country Status (10)

Country Link
US (2) US20210361634A1 (enExample)
EP (1) EP3917910A4 (enExample)
JP (1) JP2022523712A (enExample)
KR (1) KR20210119432A (enExample)
CN (1) CN113784951A (enExample)
AU (1) AU2020216887A1 (enExample)
BR (1) BR112021014956A2 (enExample)
CA (1) CA3128018A1 (enExample)
IL (1) IL285167A (enExample)
WO (1) WO2020159824A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2733405C2 (ru) 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
CA3089970A1 (en) 2018-02-07 2019-08-15 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
CN113056263A (zh) * 2018-10-30 2021-06-29 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
TW202345825A (zh) * 2022-03-30 2023-12-01 大陸商四川海思科製藥有限公司 環狀內醯胺類化合物的注射用藥物組合物及其製備方法
CN117723658A (zh) * 2023-12-08 2024-03-19 山东齐都药业有限公司 Hplc法测定丁苯酞氯化钠注射液中羟丙基倍他环糊精的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
EP1871741A4 (en) * 2005-04-04 2012-01-11 Daiamed Inc SUBSTITUTED AZETIDINONE
US9352016B2 (en) * 2011-03-09 2016-05-31 Csl Behring Gmbh Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
RU2733405C2 (ru) * 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
US20190315711A1 (en) * 2016-12-23 2019-10-17 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions

Similar Documents

Publication Publication Date Title
JP2022523712A5 (enExample)
Dunn et al. Hemodynamic, metabolic, and hematologic effects of pulsatile cardiopulmonary bypass
Gimson et al. Earlier charcoal haemoperfusion in fulminant hepatic failure
Butler et al. Amphotericin B renal toxicity in the dog
JP2022506110A5 (enExample)
Coran et al. The effect of crystalloid resuscitation in hemorrhagic shock on acid-base balance: A comparison between normal saline and Ringer's lactate solutions
Buchanan Sulphamethoxazole, hypoalbuminaemia, crystalluria, and renal failure
JP2022506109A5 (enExample)
Akyön et al. PULMONARY EMBOLISM DURING SURGERY FOR A WILMS'TUMOUR (NEPHROBLASTOMA) Case Report
Vaziri et al. Massive Mediastinal Hematoma Caused by a Double‐Lumen Subclavian Catheter
US4320110A (en) Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats
McIntosh et al. The hemodynamic effects of the injection of contrast medium (Isopaque)
RU2021125332A (ru) Терапевтические соединения и композиции
Rogers et al. Cerebral blood flow does not change following sodium nitroprusside infusion during hypothermic cardiopulmonary bypass
JP6220383B2 (ja) 非経口エスモロール製剤
Hardy et al. Fluid replacement monitoring: effect of dextran overload, norepinephrine drip, and positive pressure ventilation on systemic arterial, right atrial pulmonary wedge, and left atrial pressures in dogs
Goodwin et al. Paradoxical effect of hyperoncotic albumin in acutely burned children
Crerar-Gilbert et al. Use of inhaled nitric oxide in pulmonary embolism
Krellenstein et al. Extracorporeal membrane oxygenation for massive pulmonary thromboembolism
in't Veld et al. Stimulated sweating in chronic renal failure
Vazeery et al. CHANGES IN CARDIAC OUTPUT AND SYSTEMIC ARTERIAL PRESSURE AFTER INSERTION OF ACRYLIC CEMENT DURING TRIMETAPHAN, SODIUM NITROPRUSSIDE AND GLYCEROL TRINITRATE-INDUCED HYPOTENSION: A comparison with changes during normotension
Sadick et al. Metabolic mediation of single brief diastolic occlusion reactive hyperemic responses
Vick et al. Cardiovascular effects of guanazole
RYOJI NAGAI et al. Experimental and Clinical Studies on Extracorporeal Assisted
Hargreaves et al. Haemodynamic responses to glyceryl trinitrate: influence of rate and duration of delivery